ISONIAZID 300mg / RIFAPENTINE, 300mg, break. tab., blister

STD DORAHRIP33TB1

Valid Article

Former Code(s): DORARIIS33T1 DORAHRIP33T1
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J04AC51
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

ISONIAZID (H) / RIFAPENTINE (RPT)

Therapeutic Action

Fixed-dose combination (FDC) of two antituberculosis bactericide

Indications

Latent Tuberculosis Infection (LTI-TB)

Instructions for use

For adults and Children > 14 years

Blister packaging is the packaging of choice for antituberculosis medicines due to the unstable nature of some of them when exposed to higher temperatures and humidity.

The quantity to be ordered is calculated per tablet, not per blister.

Storage

Below 25°C ‐ Protect from sunlight ‐ Protect from humidity